Palantir received a significant upgrade from UBS to 'Buy' with a $180 price target, citing a compelling entry point after a 35% pullback. The company announced a strategic partnership with Rackspace Technology to accelerate enterprise AI deployments in regulated sectors. It also secured new collaborations with Innodata and OneMedNet, focusing on defense and healthcare data platforms. Analysts highlight strong AI-driven demand and its positioning at the center of AI and data spending, though some note the stock's valuation remains a concern for the long term.